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Abstract 
Introduction. As referrals to gender identity clinics have increased dramatically over 
the last few years, no studies focusing on older trans people seeking treatment are 
available. 
Aims. The aim of this study was to investigate the socio-demographic and clinical 
characteristics of older trans people attending a national service and to investigate 
the influence of cross-sex hormones (CHT) on psychopathology. 
Methods. Every individual over the age of 50 years old referred to a national gender 
identity clinic during a thirty months period were invited to complete a battery of 
questionnaires to measure psychopathology and clinical characteristics. Individuals 
on cross sex hormones prior to the assessment were compared with those not on 
treatment for different variables measuring psychopathology. 
Main Outcome Measures. Socio-demographic and clinical variables and measures 
of depression and anxiety (Hospital Anxiety and Depression Scale), self-esteem 
(Rosenberg Self-Esteem Scale), victimisation (Experiences of Transphobia Scale), 
social support (Multidimensional Scale of Perceived Social Support), interpersonal 
functioning (Inventory of Interpersonal Problems), and non-suicidal self-injury (Self-
Injury Questionnaire). 
Results. The sex ratio of trans females aged 50 years and older compared to trans 
males was 23.7:1. Trans males were removed for the analysis due to their small 
number (n=3). Participants included 71 trans females over the age of 50, of whom 
the vast majority were white, employed or retired, divorced and had children. Trans 
females on CHT that came out as trans and transitioned at an earlier age, were 
significantly less anxious, reported higher levels of self-esteem and presented with 
less socialization problems. When controlling for socialization problems, differences 
in levels of anxiety but not self-esteem, remained. 
Conclusion. The use of cross-sex hormones prior to seeking treatment is 
widespread among older trans females and appears to be associated with 
psychological benefits. Existing barriers to access CHT for older trans people may 
need to be re-examined. 
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Introduction 
 
Trans people of all ages have been found to face a number of difficulties such 
as interpersonal challenges (such as disclosing their gender identity) [1]; 
discrimination and victimisation [2];); low self-esteem [3]; body dissatisfaction [4]; 
rejection from family and loved ones [5]; and self-harming behaviour [6,7]. Some of 
those difficulties may be more prevalent among older trans people as ageism, 
discrimination in employment, lack of affordable housing, and lack of social and 
family support often beset older trans people [8,9,10].  
In contemporary Western societies, it is not unusual for trans people to 
present to a gender identity clinic service (GICs) at age fifty, or older. Trans older 
adults have been largely invisible in existing ageing and health research [11]. 
Generally subsumed under the broad umbrella of lesbian, gay, bisexual, and 
transgender (LGBT), there has been little information regarding how trans people 
differ from non-trans lesbian, gay, and bisexual people or how trans older adults 
differ from younger trans adults and cisgender (non-trans) older people [12].  The 
literature that does exist deals mainly with the lack of adequate and appropriate 
services for older gender non-conforming and trans people [13]. Barriers to health 
care are significant in this population due to shame, stigma, lack of educated 
caregivers and lack of insurance [14, 15, 16]. This may increase the difficulties 
accessing services forcing older trans people to self-medicate.   
Studies investigating the use of cross-sex hormones treatment (CHT) prior to 
attending gender identity clinic services among trans people of all ages, found that 
they most commonly obtain hormones via the internet, which leaves these 
individuals without the knowledge to minimize health risks [17, 18, 19]. Trans people, 
who self-prescribe cross-sex hormones tend to be predominantly trans women, and 
older when they present to gender identity clinic services; and generally have poor 
knowledge of the side effects and risks associated with cross-sex hormone treatment 
[17, 18, 19]. On the positive side, there is evidence that trans people of all ages who 
are taking cross-sex hormone treatment experience improved quality of life and less 
social distress, anxiety, and depression when compared to a population not on cross 
sex hormone treatment [20, 21, 22].  However, most of the studies exploring the 
benefits of CHT are rarely controlled for other factors known to be associated with an 
increased psychopathology, such as social support [8] and interpersonal difficulties 
[23].  
 
Aims 
 
This study had three main aims. The first was to describe the socio-
demographic and clinical features of trans people over the age of 50 years referred 
to a national gender identity clinic service during a 30 months period. The second 
aim was to collect and analyze the use and the source of cross-sex hormone 
treatment prior to referral to a gender identity clinic service and to compare trans 
people who were using cross-sex hormone treatment prior to referral with those who 
did not.  Based on the literature regarding cross-sex hormone treatment and trans 
people, it was hypothesized that the use of cross-sex hormone treatment will be 
more prevalent in trans females [17, 18, 19] and associated with less anxiety and 
depression, less self-harming behaviors and discrimination, and increased self-
esteem, social support and interpersonal functioning [20, 21, 22].  As an association 
has been found between socialization problems and psychopathology in trans 
people [8, 23] the third aim of the study was to investigate whether differences in 
psychopathology between groups still remain when controlling for socialization 
problems.  
 
Methods 
Participants and Procedures 
The sample consisted of all individuals over the age of 50 years old who were 
referred for an assessment to a national gender identity clinic service in the United 
Kingdom during a 30-month period, between November 2012 and June 2015.  
Prior to the clinical assessment every patient was invited to complete a 
battery of questionnaires to aid the assessment and diagnostic procedure. The 
assessment at the clinic consists of two appointments with independent senior 
clinicians with experience in the field of transgender health. A third appointment with 
the two clinicians, the trans person and a significant other is also organized to 
explore and to increase the social support of the individual.  Following independent 
assessments and discussion within the multi-disciplinary team the person is 
considered for entry into the treatment programme.  Treatment, including cross-sex 
hormones and gender-related surgeries is free at the point of access in the National 
Health Service (NHS) in the United Kingdom for all citizens. Patients will usually start 
cross-sex hormone treatment (CST), if there are no physical contraindications. 
Genital reconstructive surgeries are generally available to trans people after being in 
the treatment programme for a minimum of 12 months. We acknowledge that not all 
trans people wish to take cross-sex hormones or undergo gender-related surgeries; 
a growing number of trans people express a wish for partial treatment [24].  Once 
trans people have undergone their desired treatment, follow-up care can be 
organised at the service, if they wish [16].  
The study received ethical approval from the Research and Development 
Department from the Nottinghamshire Healthcare NHS Foundation Trust on behalf of 
the local ethics committee in line with Health Research Authority guidance [25]. 
 
Main Outcome Measures 
 
The Hospital Anxiety and Depression Scale (HADS) [26] is a 14-item self-
report screening scale that was originally developed to indicate the possible 
presence of anxiety and depression states in the setting of a medical non-psychiatric 
outpatient clinic.  HADS consists of two subscales, HAD-Anxiety (HAD-A) and HAD-
Depression (HAD-D), each with seven items, rated on a 4-point Likert scale (ranging 
from, as much as I always do [0]; not quite so much [1]; definitely not so much [2]; to 
not at all [3]), indicating either symptoms of anxiety or depression during the 
preceding week.  A score of 0-7 on either scale is regarding as being in the normal 
range (no symptoms), a score of 8-10 is suggestive of the presence of a mood 
disorder (possible symptoms), and a score of 11 or higher indicates the probable 
presence of a mood disorder (symptoms) of the respective state.  Maximum 
subscales scores are 21 for depression and anxiety, respectively.  Items referring to 
symptoms that may have a physical cause are not included in the scale.  The HADS 
was found to perform well in assessing the symptom severity and caseness of 
anxiety disorders and depression in both somatic, psychiatric and primary care 
patients and in the general population [27] and it has been previously used with trans 
individuals [20, 28]. 
The Rosenberg Self-Esteem Scale (RSE) [29] is a self-report measure of 
global self-esteem. Items are rated on a 4-point rating scale ranging from 0 (‘Strongly 
disagree’) to 3 (‘Strongly agree’). Its total score is calculated by summing the item 
scores with higher scores indicating higher self-esteem.  The RSE has been 
empirically validated and administered previously to trans individuals [30].  
Self-cutting and its characteristics were assessed by means of the Self-Injury 
Questionnaire (SIQ) [31]. Participants were asked whether they had ever 
deliberately cut themselves (yes/no) and if they had, how long ago they last did this 
(in the last week, month, several months ago, more than a year ago, or never). If 
they injured themselves during the last week or month, they were also asked to 
indicate which body parts were injured; how many days/month and times/day the 
cutting occurred; and how often and how much pain they felt during the cutting. This 
questionnaire has also been used in the trans population [6]. 
The Experiences of Transphobia Scale [2] assesses experiences of 
discrimination or victimization on the basis of gender identity or gender presentation. 
The questionnaire was based on the Transgender Violence Study and measured 
people’s lifetime experiences of violence and harassment and experiences of any 
form of economic discrimination as a result of being trans (e.g., verbal abuse, 
physical abuse, fired from a job, problems getting a job, and problems getting health 
or medical services due to gender identity or presentation). All five items are to be 
rated on a four-point Likert scale ranging from 0 (‘never‘) to 3 (‘several times’). 
The Multidimensional Scale of Perceived Social Support (MSPSS) [32] is 
a 12-item, self-report scale designed to tap social support from family, friends, and 
significant others. Items are rated on a 7-point Likert scale ranging from 1 (‘very 
strongly agree’) to 7 (‘very strongly disagree’). The instrument includes three 
subscales to address these three types of support (family, friends, significant others). 
The mean total and subscale scores range from 1 to 7, and a higher score indicates 
greater perceived social support. This scale has recently been used in trans 
populations [8]. 
The Inventory of Interpersonal Problems (IIP-32) [33] measures 
interpersonal difficulties. It consists of 32 items to be rated on a 5-point Likert scale 
ranging from 0 (‘Not at all’) to 4 (‘Extremely’). There are eight subscales of 
interpersonal problems: Hard to be Assertive, Hard to be Sociable, Hard to be 
Supportive, Hard to be Involved, Too Dependent, Too Caring, Too Aggressive, and 
Too Open. A total mean score provides a global measure of interpersonal distress. 
Higher subscale scores indicate greater interpersonal difficulties. The IIP-32 is a 
shortened version of the original IIP, yet the psychometric properties are retained; a 
confirmatory factor analysis demonstrated high reliability with alpha coefficients of 
0.70 to 0.88 [33]. The IIP-32 has been used successfully in both non-clinical [34] and 
clinical samples [23].  
  
Data Analysis 
All quantitative data analyses were performed by means of SPSS 22 [35]. The 
Kolmogorov-Smirnov Test was used to assess whether the variables were normally 
distributed. Given that only six variables were normally distributed (age of first 
referral, HADS-anxiety, Rosenberg Self-Esteem, MSPSS-Family, IIP-32 Nurturance 
and Total), non-parametric test were applied. For the first aim, descriptive statistics 
were applied.  A quantitative analysis was performed for the second and third aim. 
The overall population will be divided into two groups: individuals on cross-sex 
hormone treatment prior to attending the gender identity clinic service and not on 
cross-sex hormone treatment. Both groups will be compared using the Chi square 
test statistic (for nominal variables), the Mann-Whitney U test [for (non-)normal 
continuous variables, aim 2] and (M)AN(C)OVAs (for normal distributed continuous 
variables, aim 3).  The level of significance used was p < 0.05. 
 
Results 
Sociodemographic and Clinical Characteristics 
During the recruitment period of 30 months 689 individuals were referred to 
the clinic, of whom 77 (11.2%) were aged 50 years and older.  Three people did not 
attend their appointment. Hence, the total sample consisted of 71 (96.2%) trans 
females and 3 (3.8%) trans males. Table 1 describes the socio-demographic and 
clinical characteristics of the total sample. 
 
[Insert Table 1 here] 
 
The sex ratio of older trans females compared with trans males was 23.7:1.  
The mean age at the time of the assessment of the participants was 58.9 years (SD 
= 6.5). In view of the small number of older trans males attending the clinical service, 
consequent analysis was only performed for the 71 trans females.  
Out of the 71 trans females, 33 (46.5%) were not taking cross-sex hormone 
treatment prior to their first clinic appointment and 38 (53.5%) were. The mean age 
of the trans female group at the time of the assessment and first contact with gender 
services was 59.32 years (SD = 6.67). The mean age of coming out was 47.39 years 
(SD = 13.80) and the mean age of social gender role transition was 56.02 years (SD 
= 9.65). Two people had not come out as trans and 21 people had not transitioned 
prior to their first appointment. Coming out concerns the process of becoming open 
about your experienced gender with yourself, other people close to you and/or 
publicly.  Transition refers to a period of time when individuals change from the 
gender role associated with their sex assigned at birth to a different gender role. For 
many people, this involves learning how to live socially in another gender role; for 
others this means finding a gender role and expression that are most comfortable for 
them. Transition may or may not include feminization or masculinization of the body 
through cross-sex hormones or other medical procedures. The nature and duration 
of transition are variable and individualized [14]. Social gender role transition is the 
social portion of a transition, in which a trans person makes aware of their gender 
identity. Some parts of social transition can include telling people about one’s gender 
identity, whether or not they are aware of assigned gender at birth and/or trans 
status; changing name used within social interactions; asking others to use different 
pronouns, titles and other gendered language; and changing gender expression. 
Table 2 summaries the differences in rates of individuals taking up CHT prior to 
referral. Individuals who presented to the service on cross-sex hormone treatment 
were statistically significantly younger at the time of the assessment. This group also 
came out and transitioned significantly earlier than those trans females not on 
treatment (See Table 2). 
[Insert Table 2 here] 
 
The vast majority of the trans females in the present study were white, 
employed or retired; divorced, single or widowed, and had children, irrespective of 
the use of cross sex hormone treatment prior to their first appointment at the gender 
clinic service. Additionally, the majority of trans females report a medical history, with 
just over half reporting previous mental health problems, with no significant 
differences between trans females who use and do not use cross-sex hormone 
treatment. The levels of self-harm or non-suicidal self-injury (NSSI) were small with 
16.9% of the trans females reporting a life time NSSI. The main socio-demographic 
and clinical variables of the trans female sample with and without cross-sex hormones 
treatment are displayed in Table 3. 
 
[Insert Table 3 here] 
 
Of the 38 trans females on cross-sex hormone treatment (CST) 21 (55%) had 
obtained these via the Internet. The CST used was oestrogens, either in tablet form 
or as patches. Eleven out of 21 (52%) trans females also used at least one additional 
drug which blocked testosterone, including cyproterone acetate, spironolactone and 
finasteride. Thirteen people (34%) had obtained CST via a private physician; and 4 
people (11%) received their hormone treatment from physicians working in the NHS 
(three via their primary care physician and one via a local endocrinologist). 
 
 
Cross-sex hormone treatment versus no treatment 
When analyzing the two groups of trans females, the study found significant 
differences between trans females with and without CST on the HADS scale scores, 
trans females on CST were significantly less anxious (HADS-A) compared to trans 
females not on CST. Interestingly, no significant difference in the level of HADS-D 
between the two groups were found. Additionally, trans females on CST report a 
significantly higher level of self-esteem compared to trans females not on CST. 
The study found no significant overall differences between trans females with 
and without CST on the different MSPSS scale scores.  
Regarding interpersonal problems, trans females on CST were found to 
present with significantly less problems with socialization and in general 
interpersonal functioning than trans females who do not use CST. Finally, with 
respect to transphobic experiences no significant differences were found between 
trans females with(out) cross-sex hormone use (See Table 4). 
 
[Insert Table 4 here] 
A multi-variant analysis (MANCOVA) was performed to determine whether 
there were any independent effects (See Table 5). As patients were found to differ 
with respect to IPP-32 socialisation having taken CST or not, we controlled for both 
variables while comparing patients with(out) CST on the HADS scales and the 
Rosenberg Self-Esteem scale. Overall, we did not find significant differences 
between trans females with and without CST on the HADS scale scores while 
controlling for socialization problems [Wilks’ Lambda = 0.91, F(2,61) = 2.97, ns]. On 
the univariate level, the difference in the HADS-A between the two groups remained 
and trans females on CST were found to be significantly less anxious (HADS-A) 
compared to trans females not on CST. Additionally, anxiety/depression were 
significantly positive related to socialization problems (p<0.05).  
Trans females with and without CST did not differ on self-esteem while 
controlling for socialization problems. Additionally, higher self-esteem was negatively 
related to problems with socialization (p<0.01). 
 
[Insert Table 5 here] 
 Discussion 
There has not been any systematic information investigating socio-
demographic and clinical characteristics of older trans people. There is no 
systematic collection of such data in this group other than case reports [36, 37], case 
series [38, 39] and population samples obtained via the Internet [40] or postal 
questionnaires [12, 41].  Similarly, there has been no research investigating the role 
of cross-sex hormone treatment in older trans people.  This is the first study to 
exclusively focus on trans people aged 50 years and beyond who seek treatment at 
a gender identity clinic service.  This is an important area as older trans people 
remain invisible in research studies and often experience double discrimination; 
being trans as well as being older. Moreover, they are at a higher risk of developing 
adverse effects from cross-sex hormone treatment [42, 43], as they are more prone 
to co-morbidities as well as using CHT without medical advice and supervision. 
The study found that overwhelming majority of older people presenting at 
gender identity clinic services over the age of 50 years old are trans females, with a 
sex ratio of 23.7:1 over trans males. To our knowledge, this has not been 
documented formally in the empirical literature and is distinctly different from the sex 
ratio of trans adolescents and trans adults, which points towards near parity for 
adolescents and adults [18, 19, 44, 45]. 
Whether trans people who transition later in life constitute a different group 
compared to their younger counterparts has been vociferously debated [46, 47].  
Trans people who transition later in life may have different psychosocial 
characteristics, but the exact aetiology remains unclear. It remains to be seen how 
clinically relevant further classification in this context is; ethically there is general 
agreement in medicine that in ethical matters like cases should be treated alike [48].  
The mainstay physical treatment options remain the same and include cross-sex 
hormone treatment and gender-related surgeries [14, 16].  There is a higher risk 
associated with these treatments for older people, which should be discussed with 
patients on an informed consent model basis [42, 43, 48, 49].  Cross-sex hormone 
use was present in 54% of gender clinic referrals, of whom more than 50% sourced 
the hormones via the Internet. It is concerning that 28% of older trans people who 
presented at the clinical service had obtained hormone treatment via the Internet 
without medical advice.  This is significantly higher than previously reported [17] and 
it may be a reflection of the significant barriers to treatment for older trans people. 
Ageism, discrimination in employment, and lack of social and family support plus 
lack of gender identity clinic services, long waiting lists, lack of funding [8, 9, 10] may 
be reasons as to why older trans people obtain treatment without medical assistance 
or support [9, 17]. Moreover, it could be argued that overly prescriptive pathways to 
access hormone treatment in Standards of Care [14, 16] further increase barriers to 
treatment. 
The finding that trans females who presented to the clinical service on cross-
sex hormone treatment were significantly younger than their counterparts, who were 
not on CST may be a reflection of the higher accessibility to the Internet associated 
with a younger age. Older people may be less skilled in using computer technology, 
which makes obtaining hormones via the Internet more difficult. An alternative 
explanation may be that older people are less willing to initiate hormone treatment, 
which is not prescribed and monitored by a physician.  The study also showed that 
those on CHT came out and transitioned significantly earlier than those trans 
females not on treatment.  As we do not know how long people were taking cross-
sex hormone treatment the direction of the association between starting hormone 
treatment, coming out as trans and time of transition remains unknown. Interestingly, 
independent of hormone treatment the time between coming out as trans and age of 
transition remains around a decade. This is a considerable amount of time and may 
well be related to family and work responsibilities, although future research may want 
to investigate the specific underlying reasons for this.  
The life-time prevalence of non-suicidal self-injury (NSSI, i.e., cutting) was 
16.9% in our sample of older trans females, which is much lower than the prevalence 
of NSSI in younger trans females (26.2%) [6], but significantly higher than the life-
time prevalence of NSSI in an adult community sample (5.9%) [50]. As most injurers 
report that NSSI functions to alleviate negative emotions further research should 
focus on underlying aetiology and preventative measures. 
Older trans females who use cross-sex hormones were found to be 
significantly less anxious and reported a significantly higher self-esteem compared to 
older trans females who do not use hormones. The association disappeared for self-
esteem when controlled for problems with socialization. As older trans females who 
use cross-sex hormones experienced less problems with socialization than older 
trans females who did not use hormones, controlling for this variable known to 
predict psychopathology was important. This is one of the few studies that have 
controlled for predictive variables when studying the role of treatment in trans 
people. The study shows that when controlling interpersonal difficulties the levels of 
anxiety in trans females on CHT is consistent with other research of younger trans 
people who use cross-sex hormones and highlights the psychological and social 
benefits that may be associated with cross-sex hormone treatment for trans people 
[20, 21, 22]. However, due to the cross sectional nature of this study cause and 
effect could not be concluded. It must also be acknowledged that these trans 
females as autonomous agents have sought access to hormone treatment without 
assistance or support from gender identity clinic services.  Given the benefits 
patients may derive from cross-sex hormone treatment and bearing in mind the risks 
associated with CST which is not adequately monitored, particularly in older people, 
a re-evaluation of the function and purpose of gender identity clinic services is timely. 
A limitation of the study is the cross-sectional nature of the data. Future 
research could investigate underlying motives as to why people obtain and use 
cross-sex hormone treatment without medical advice, what the associated risks are, 
if any, and why people transition later in life. From the current data, it is not possible 
to determine whether the psychological benefits associated with the use of hormone 
treatment predate or are a consequence of disclosure of experienced gender and/or 
social gender role transition. It may also be that those with a better self-esteem, less 
psychopathology and less problems with socialization feel more confident to 
commence treatment without medical advice. They may use the support and advice 
of their friends who may also be taking CST. Longitudinal data would provide the 
ideal avenue to explore this. The study is also limited by selecting a specific 
population of treatment seeking individuals and in a country where the waiting list for 
a first appointment at a gender identity clinic service is long. Hence, the results may 
not be generalizable to other older trans females who do not access clinical services 
or to other countries with a different healthcare system.  The research makes use of 
self-reported questionnaires, and although most are adequately validated and have 
been used in trans populations, future research could use structured clinical 
interviews to differentiate the clinical group from those with and without anxiety. A 
final note on the generalizability of these findings is that there are particularities with 
regards to medical treatment and legislation for trans person people in the UK. For 
example, some aspects of gender reassignment treatment (e.g., cross-sex hormone 
treatment and/or genital reconstructive surgeries) are available through the NHS free 
at the point of access, and the Gender Recognition Act 2004 provides legal 
recognition of a trans individual’s experienced gender. In addition, the Sex 
Discrimination (Gender Reassignment) Regulations Act 1999, and its amendment in 
2008, deemed it unlawful to discriminate on the basis of gender reassignment within 
employment and vocational training, as well as within the provision of goods, 
facilities, and services. Consequently, the experience of living as trans in the United 
Kingdom may be different from living as trans in other countries. A cross-cultural 
validation of the findings would be expedient because differences in legislation and 
health service provision are likely to affect the experience of being trans [23]. 
Conclusion 
The majority of older people presenting at gender identity clinic services over the age 
of 50 years old are trans females.  After coming out as trans older people take on 
average about a decade to fully transition, which may be related to employment or 
family responsibilities.  More than a quarter of this older trans population had 
obtained hormone treatment via the Internet without medical advice.  Older trans 
females who use cross-sex hormones were found to be significantly less anxious 
compared to older trans females who do not use hormones, even when controlled for 
interpersonal difficulties.  Older female trans people clearly derive benefits from 
cross-sex hormone treatment.  Clinicians need to provide education regarding cross-
sex hormone treatment and advice regular monitoring to reduce risks associated 
with cross-sex hormone treatment. 
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Table 1. Socio-demographic and clinical characteristics of the total sample of Trans females 
and Trans males, over 50 years (n= 74) 
 
 
 
 
 
 
 
 Trans Females 
(n=71) 
Trans Males 
(n=3) 
Total 
(n=74) 
 n (%) n (%) n (%) 
Ethnic origin 
  White 
  Other 
 
70 
1 
 
(98.6) 
(1.4) 
 
3 
0 
 
(100) 
(0) 
 
73 
1 
 
(98.6) 
(1.4) 
Employment 
status 
  Employed 
  Retired 
  Disabled 
  Unemployed 
  Volunteer 
  Housewife 
 
 
24 
14 
7 
6 
1 
1 
 
 
(33.8) 
(19.7) 
(9.9) 
(8.5) 
(1.4) 
(1.4) 
 
 
1 
0 
1 
1 
0 
0 
 
 
(33.3) 
(0) 
(33.3) 
(33.3) 
(0) 
(0) 
 
 
25 
14 
8 
7 
1 
1 
 
 
(33.8) 
(18.9) 
(10.8) 
(9.5) 
(1.4) 
(1.4) 
Civil Status 
  Single 
  Married 
  Civil Partner 
  Divorced 
  Widowed 
  In a relation 
 
11 
18 
1 
34 
5 
1 
 
(15.5) 
(25.4) 
(1.4) 
(47.9) 
(7) 
(1.4) 
 
1 
1 
1 
0 
0 
0 
 
(33.3) 
(33.3) 
(33.3) 
(0) 
(0) 
(0) 
 
12 
19 
2 
34 
5 
1 
 
(16.2) 
(25.7) 
(2.7) 
(45.9) 
(6.8) 
(1.4) 
Children 
  No 
  Yes 
 
26 
45 
 
(36.6) 
(63.4) 
 
1 
2 
 
(33.3) 
(66.7) 
 
27 
47 
 
(36.5) 
(63.5) 
Medical history 
  Medical, No 
  Medical, Yes 
 
6 
65 
 
(8.5) 
(91.5) 
 
1 
2 
 
(33.3) 
(66.7) 
 
7 
67 
 
(9.5) 
(90.5) 
Psychiatric 
history   
Psychiatric, No 
Psychiatric, Yes 
 
32 
39 
 
(45.1) 
(54.9) 
 
1 
2 
 
(33.3) 
(66.7) 
 
33 
41 
 
(44.6) 
(55.4) 
Self-harm 
  No 
  Yes 
 
68 
3 
 
(95.8) 
(4.2) 
 
3 
0 
 
(100) 
(0) 
 
71 
3 
 
(95.9) 
(4.1) 
Table 2. Means (with standard deviations) of the age, age at assessment, referral, coming 
out and transition of trans females over 50 years with and without cross-sex hormones 
treatment (CHT) 
 Not on CHT 
 
On CHT 
 
Total Mann-
Whitney 
U 
 M (SD) M (SD) M (SD)  
Age at 
assessmen
t 
(n = 71) 
60.82 (7.28) 58.03 (5.87) 59.32 (6.67) 492 
Age of first 
referral 
(n=71) 
60.45 (7.34) 56.79 (6.59) 58.49 (7.14) 455.5* 
Age of 
coming  
out 
(n=69) 
51.55 (14.04) 43.58 (12.61) 47.39 (13.80) 373.5** 
Age of 
transition 
(n=49) 
59.35 (10.65) 53.72 (8.32) 56.02 (9.65) 189.5* 
*  p < 0.05, ** p < 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Socio-demographic and clinical characteristics of trans females over 50 years, with 
and without cross-sex hormones treatment (CHT) (n=71) 
 Not on CHT On CHT Total Χ2 
 n (%) n (%) n (%)  
Ethnic origin 
  White 
  Other 
 
33 
0 
 
(100) 
(0) 
 
37 
1 
 
(97.4) 
(2.6) 
 
70 
1 
 
(98.6) 
(1.4) 
 
.88 
Employment 
status 
  Employed 
  Retired 
  Disabled 
  Unemployed 
  Volunteer 
  Housewife 
 
 
8 
9 
5 
1 
0 
1 
 
 
(33.3) 
(37.5) 
(20.8) 
(4.2) 
(0.0) 
(4.2) 
 
 
16 
5 
2 
5 
1 
0 
 
 
(55.2) 
(17.2) 
(6.9) 
(17.2) 
(3.4) 
(0) 
 
 
24 
14 
7 
6 
1 
1 
 
 
(45.3) 
(26.4) 
(13.2) 
(11.3) 
(1.9) 
(1.9) 
 
 
9.37 
Civil Status 
  Single 
  Married 
  Civil Partner 
  Divorced 
  Widowed 
  In a relation 
 
7 
12 
0 
11 
2 
0 
 
(21.9) 
(37.5) 
(0) 
(34.4) 
(6.3) 
(0) 
 
4 
6 
1 
23 
3 
1 
 
(10.5) 
(15.8) 
(2.6) 
(60.5) 
(7.9) 
(2.6) 
 
11 
18 
1 
34 
5 
1 
 
(15.7) 
(25.7) 
(1.4) 
(48.6) 
(7.1) 
(1.4) 
 
8.80 
Children 
  No 
  Yes 
 
12 
21 
 
(36.4) 
(63.6) 
 
14 
24 
 
(36.8) 
(63.2) 
 
26 
45 
 
(36.6) 
(63.4) 
 
0.002 
Medical history 
  Medical, No 
  Medical, Yes 
 
2 
31 
 
(6.1) 
(93.9) 
 
4 
34 
 
(10.5) 
(89.5) 
 
6 
65 
 
(8.5) 
(91.5) 
 
.46 
Psychiatric 
history   
Psychiatric, No 
Psychiatric, Yes 
 
 
15 
18 
 
 
(45.5) 
(54.5) 
 
 
17 
21 
 
 
(44.7) 
(55.3) 
 
 
32 
39 
 
 
(45.1) 
(54.9) 
 
 
0.004 
Self-harm 
  No 
  Yes 
 
27 
6 
 
(81.8) 
(18.2) 
 
32 
6 
 
(84.2) 
(15.8) 
 
59 
12 
 
(83.1) 
(16.9) 
 
0.07 
 
 
 
 
  
 
 
 Table 4. Means (with standard deviations) of the MSPSS, IPP-32, and Transphobia Scale 
for trans females over 50 years with and without cross-sex hormones treatment (CHT)  
 Not on treatment Taking cross-sex 
hormones 
Total Mann-
Withney 
U 
 M (SD) M (SD) M (SD)  
HADS (n=68) 
  Anxiety 
  Depression 
 
7.84 
6.68 
 
(3.90) 
(4.85) 
 
5.03 
4.62 
 
(3.44) 
(4.03) 
 
6.30 
5.56 
 
(3.89) 
(4.51) 
 
341** 
432 
RSE (n=69) 
  Total 
 
19.59 
 
(6.34) 
 
23.05 
 
(5.32) 
 
21.45 
 
(6.03) 
 
420.5* 
MSPSS (n=68) 
  Significant others 
  Family  
  Friends 
  Total 
 
19.57 
15.53 
16.10 
51.20 
 
(8.89) 
(8.74) 
(8.25) 
(21.69) 
 
20.32 
16.24 
19.87 
56.42 
 
(7.69) 
(6.87) 
(5.70) 
(14.09) 
 
19.99 
15.93 
18.21 
54.12 
 
(8.19) 
(7.70) 
(7.14) 
(17.89) 
 
600 
553 
464.5 
516 
IIP-32: Problems  
  Competition 
  Socialization 
  Nurturance 
  Independence 
  Total 
 
1.03 
-0.91 
-0.42 
0.55 
1.31 
 
(1.13) 
(1.09) 
(1.22) 
(1.02) 
(0.58) 
 
0.81 
-1.46 
-0.59 
0.42 
0.94 
 
(1.10) 
(1.16) 
(0.88) 
(0.96) 
(0.59) 
 
0.92 
-1.20 
-0.51 
0.48 
1.11 
 
(1.11) 
(1.15) 
(1.05) 
(0.98) 
(0.61) 
 
516 
375* 
532 
586.5 
335.5** 
Transphobia 
(n=70) 
Total 
 
1.81 
 
(2.08) 
 
2.05 
 
(1.79) 
 
1.94 
 
(1.91) 
 
528 
*  p < 0.05, ** p < 0.01 
HADS: Hospital Anxiety and Depression Scale; RSE: Rosenberg Self-Esteem Scale; IIP-32: Inventory of Interpersonal 
Problems; MSPSS: Multidimensional Scale of Perceived Social Support  
 
 
 
 
 
 
 
 
 
 
 
Table 5. Means (with standard deviations) of the HADS and the Rosenberg Self-esteem 
Scale controlled for IPP-32 Socialization for trans females over the age of 50 years with and 
without cross-sex hormones treatment (CHT) 
 Not on CHT On CHT Total F 
 M (SD) M (SD) M (SD)  
HADS (n=68) 
  Anxiety 
  Depression 
 
7.80 
6.83 
 
(3.96) 
(4.86) 
 
5.14 
4.75 
 
(3.42) 
(4.02) 
 
6.35 
5.70 
 
(3.88) 
(4.51) 
 
5.82* 
1.08 
RSE (n=69) 
  Total 
 
19.10 
 
(6.34) 
 
22.86 
 
(5. 27) 
 
21.18 
 
(6.02) 
 
3.33 
*  p < 0.05 
HADS: Hospital Anxiety and Depression Scale; RSE: Rosenberg Self-Esteem Scale 
 
 
 
